A Pilot Study of Daratumumab (CD38 Antagonist) in Patients With Metastatic Renal Cell Carcinoma or Muscle Invasive Bladder Cancer
Phase of Trial: Phase 0
Latest Information Update: 19 Dec 2018
At a glance
- Drugs Daratumumab (Primary)
- Indications Bladder cancer; Renal cell carcinoma; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Dec 2018 Planned End Date changed from 1 Mar 2020 to 1 Mar 2019.
- 29 May 2018 Status changed from not yet recruiting to recruiting.
- 11 Apr 2018 Planned End Date changed from 1 Mar 2019 to 1 Mar 2020.